Bristol/ImClone Pull, Will Resubmit, Erbitux sBLA For Lung Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
ImClone Systems and Bristol-Myers Squibb are pulling a supplemental BLA for Erbitux (cetuximab) to treat non-small cell lung cancer, saying they plan to resubmit the application as soon as possible after answering manufacturing questions posed by FDA
You may also be interested in...
FDA Agrees To Accelerated Approval For Myozyme Scale-Up, Genzyme Says
The 2,000L version of Myozyme on track for approval with a post-market confirmatory trial in February; user fee date extended while FDA reviews REMS submission.
Amylin Speculation Intensifies: Byetta LAR May Be Delayed
Comparability studies could mean filing is impossible for first half of 2009, Amylin says.
Lilly Snatches ImClone Away From Bristol
Lilly’s $6.5 billion acquisition of ImClone will create an oncology “powerhouse” with 18 cancer drugs in clinical development.